Sonic Healthcare Limited
Sonic Healthcare Limited (SKHCF) Stock Overview
Explore Sonic Healthcare Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
8.9B
P/E Ratio
38.04
EPS (TTM)
$0.73
ROE
0.05%
SKHCF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Sonic Healthcare Limited (SKHCF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $16.38.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 38.04 and a market capitalization of 8.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Sonic Healthcare Limited offers medical diagnostic services to medical practitioners, hospitals, community health services, and their collective patients. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It also offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, after-hours general practice services, general practice IT solutions, and community-based healthcare services. The company operates in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, Belgium, and internationally. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.
Colin Stephen Goldschmidt F.A.I.C.D., F.R.C.P.A., M.B.B.Ch.
42,000
Grosvenor Place, Sydney, NSW
2010